Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

80
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
80
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

178
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
178
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

944
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
944
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

128
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
128
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

680
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
680
Exercise and Cardiac Output01:17

Exercise and Cardiac Output

1.6K
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking triglycerides in the management of ASCVD.

European journal of preventive cardiology·2026
Same author

H3K9me3 regulates IFNγlo Tex cell differentiation to promote colon tumor liver metastasis.

Molecular cancer therapeutics·2026
Same author

Alternative Splicing of TPM1 Mediated by SRPK3 Drives Cardiac Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.

Circulation·2026
Same author

Comparative performance of ChatGPT and DeepSeek in interpreting the 2025 ESICM guidelines on sepsis fluid therapy.

Digital health·2026
Same author

Author Correction: Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors.

Nature communications·2026
Same author

Flow-mediated endothelial remodeling and inflammation drive developmental vascular susceptibility in ldlr loss of function.

Nature communications·2026

Related Experiment Video

Updated: Nov 25, 2025

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.7K

Eosinophils improve cardiac function after myocardial infarction.

Jing Liu1,2, Chongzhe Yang1, Tianxiao Liu1,2

  • 1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.

Nature Communications
|December 17, 2020
PubMed
Summary
This summary is machine-generated.

Eosinophils protect the heart after myocardial infarction (MI). Depleting these cells worsens cardiac dysfunction, but their presence and specific proteins like mEar1 prevent cell death and inflammation, establishing a cardioprotective role.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.8K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

4.2K

Related Experiment Videos

Last Updated: Nov 25, 2025

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.7K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.8K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

4.2K

Area of Science:

  • Cardiology
  • Immunology
  • Cell Biology

Background:

  • Eosinophil counts and cationic proteins are implicated in coronary heart disease risk.
  • Changes in eosinophil levels post-myocardial infarction (MI) require further investigation.

Purpose of the Study:

  • To investigate the role of eosinophils in cardiac dysfunction and repair following myocardial infarction (MI).
  • To elucidate the mechanisms by which eosinophils exert their effects in the post-MI heart.

Main Methods:

  • Analyzing blood and heart eosinophil counts in humans and mice post-MI.
  • Utilizing genetic and inducible eosinophil depletion models (∆dblGATA mice).
  • Performing in vitro studies on cardiomyocyte death, fibroblast activation, and neutrophil adhesion.

Main Results:

  • Eosinophil depletion exacerbated cardiac dysfunction, cell death, and fibrosis post-MI.
  • Eosinophils, via IL4 and mEar1, protected cardiomyocytes from death and inhibited fibroblast activation and neutrophil adhesion.
  • In vitro eosinophils and recombinant mEar1 protein corrected cardiac dysfunction in deficient mice.

Conclusions:

  • Eosinophils play a crucial cardioprotective role in the heart after myocardial infarction.
  • Eosinophil-derived IL4 and mEar1 are key mediators of this protective effect.
  • Targeting eosinophils may offer novel therapeutic strategies for post-MI recovery.